An antibody from a Tanzanian woman discovered during screening for anti-HIV antibodies shows a strong therapeutic potential in a preclinical study. Named 04_A06, it neutralised (blocked) 97.3% of over 300 HIV strains tested, and blocked 77% of viruses resistant to other antibodies. In humanised mice – designed to have an immune system like ours – the antibody completely suppressed viral load after stopping treatment for more than a month.
Apart from the potential therapeutic promise, the broadly neutralising antibody could also be valuable for prevention as the same researchers modelled it to confer 93% protection when used as PrEP. Findings were published by Dr Lutz Gieselmann and colleagues in the journal Nature Immunology.
Read the full news story at aidsmap.
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.